0 Items
Select Page

Yellow Fever Virus

According to the World Health Organization, there are 47 countries in Africa and Central & South America that are either endemic for, or have regions that are endemic for yellow fever. A 2013 study estimated the burden of yellow fever was 84 000–170 000 severe cases and 29 000–60 000 deaths.

The Native Antigen Company offers a range of recombinant Yellow Fever virus antigens, highly specific monoclonal antibodies and donor sera from vaccine recipients to support research into YFV infection and assay development.

Yellow Fever Virus Background

Yellow fever is an acute haemorrhagic disease caused by the Yellow Fever virus (YFV), a member of the Flaviviridae family of viruses. Clinical symptoms of the disease include fever, muscle pain, nausea and vomiting. In a small percentage of patients, the liver and kidneys are affected leading to jaundice, and in some cases death. In the sylvatic cycle, the virus is transmitted to non-human primates via mosquitoes of the Haemagogus and Sabethes genera. Whereas the Aedes aegypti mosquito is responsible for the transmission of YFV to humans in urban areas. Yellow fever virus is endemic in tropical areas of Africa and Central/South America where the vector is widespread.

In the late 1930’s a safe and effective, attenuated vaccine was developed against the YFV, which confers long-term immunity. Since its introduction, the vaccine has been used successfully to immunize individuals in areas where YFV is endemic. However, vaccination coverage is sparse and lack of immunity continues to contribute to widespread outreaks.

Diagnosis of yellow fever is complicated by the fact that early symptoms of the infection can be confused with other haemorrhagic diseases including Dengue, Ebola and Zika. Differential diagnosis is therefore an important consideration in areas where other flaviviruses such as Dengue and Zika co-circulate.

References

  1. Norrby E (2007). Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine. J Exp Med. 204 (12):277

Yellow Fever Virus Antigens

Using our proprietary mammalian cell expression system, we have generated highly pure YFV NS1 protein in its hexameric conformation, with native glycosylation and folding. Our yellow fever NS1 proteins are ideal for use as controls and standards in ELISA, LFD and related tests for measuring patient NS1 in early infection. Our Yellow Fever virus antigen is an excellent target for developing serological assays.  

Yellow Fever Virus Antibodies

Using our recombinant YFV NS1 proteins, we have raised a panel of antibodies to NS1, all of which are highly specific and show no cross-reactivity with other flaviviral NS1 proteins, including Dengue, Zika, West Nile and Japanese Encephalitis viral proteins. These antibodies are ideal for the development of immunoassays to measure the level of YFV NS1 proteins.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

The Why and How of Protein Conjugation

In this blog, Lead Assay Development Scientist, Toni Ertl discusses the basics of protein conjugation and introduces our new range of conjugation kits for the labelling of antigens and antibodies.Detecting Proteins If you’re trying to detect or measure the presence...

Going Viral: Why We Need New Diagnostics For a Safe and Effective Dengue Vaccine

This article is taken from European Biopharmaceutical Review January 2020, pages 44-46. © Samedan Ltd.The Dengue VirusDengue is the world’s most prevalent and consequential arboviral disease. Current estimates indicate that as many as 390 million dengue infections...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

15 + 2 =

Live Customer Feedback

Join our mailing list

* indicates required